Cala Health, which develops bioelectrical therapies for chronic diseases, has closed a $50 million Series C financing round
Cala Health, which develops bioelectrical therapies for chronic diseases, has closed a $50 million Series C financing round from Novartis, Baird Capital, LifeSci Venture Partners, TriVentures, and others.
The company will use the funds to launch Cala Trio, its wearable therapeutic device for the treatment of essential tremor. Essential tremor is a common movement disorder affecting over 7 million Americans and millions more worldwide. The condition is marked by hand tremors that make it difficult, if not impossible, to perform daily activities like eating, drinking, and writing.
The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualised peripheral nerve stimulation. While the first indication for Cala Health’s wearable therapy is essential tremor, the company will also use the funds to continue developing new therapies in neurology, cardiology and psychiatry.
The company, based in San Francisco, was cofounded by Kate Rosenbluth, Scott Delp and Serena Wong. Rosenbluth, Cala Health’s CEO has developed cutting-edge neurotherapies with Brainlab, Autonomic Technologies, and Genentech. She was a lecturer and fellow in Stanford Technology Ventures Program and Biodesign and a Postdoctoral Fellow in UCSF Neurosurgery. To date the company has raised a total of $71.3 million.